BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 22048466)

  • 1. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
    King DP; Paciga S; Pickering E; Benowitz NL; Bierut LJ; Conti DV; Kaprio J; Lerman C; Park PW
    Neuropsychopharmacology; 2012 Feb; 37(3):641-50. PubMed ID: 22048466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
    Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
    JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
    Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
    JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varenicline: a first-line treatment option for smoking cessation.
    Garrison GD; Dugan SE
    Clin Ther; 2009 Mar; 31(3):463-91. PubMed ID: 19393839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for smoking cessation: an overview and network meta-analysis.
    Cahill K; Stevens S; Perera R; Lancaster T
    Cochrane Database Syst Rev; 2013 May; 2013(5):CD009329. PubMed ID: 23728690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
    Tonstad S
    J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006103. PubMed ID: 18646137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo.
    Gonzales D; Jorenby DE; Brandon TH; Arteaga C; Lee TC
    Addiction; 2010 Nov; 105(11):2002-13. PubMed ID: 20819082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm.
    Rose JE; Behm FM
    Am J Psychiatry; 2014 Nov; 171(11):1199-205. PubMed ID: 24934962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Lindson-Hawley N; Thomas KH; Fanshawe TR; Lancaster T
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD006103. PubMed ID: 27158893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
    West R; Baker CL; Cappelleri JC; Bushmakin AG
    Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine receptor partial agonists for smoking cessation.
    Cahill K; Stead LF; Lancaster T
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006103. PubMed ID: 17253581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline: for smoking cessation.
    Rao J; Shankar PK
    Kathmandu Univ Med J (KUMJ); 2009; 7(26):162-4. PubMed ID: 20071853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
    Bailey SR; Crew EE; Riske EC; Ammerman S; Robinson TN; Killen JD
    Paediatr Drugs; 2012 Apr; 14(2):91-108. PubMed ID: 22248234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.
    Xenakis JG; Kinter ET; Ishak KJ; Ward AJ; Marton JP; Willke RJ; Davies S; Caro JJ
    Pharmacoeconomics; 2011 Jun; 29(6):497-510. PubMed ID: 21452908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which is the best primary medication for long-term smoking cessation--nicotine replacement therapy, bupropion or varenicline?
    Doggrell SA
    Expert Opin Pharmacother; 2007 Dec; 8(17):2903-15. PubMed ID: 18001252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.